Literature DB >> 14764660

Cutting edge: in vitro-generated tolerogenic APC induce CD8+ T regulatory cells that can suppress ongoing experimental autoimmune encephalomyelitis.

Douglas E Faunce1, Ania Terajewicz, Joan Stein-Streilein.   

Abstract

APC exposed to TGFbeta2 and Ag (tolerogenic APC) promote peripheral Ag-specific tolerance via the induction of CD8(+) T regulatory cells capable of suppressing Th1 and Th2 immunity. We postulated that tolerogenic APC might reinstate tolerance toward self-neuronal Ags and ameliorate ongoing experimental autoimmune encephalomyelitis (EAE). Seven days after immunization with myelin basic protein (MBP), mice received MBP-specific tolerogenic APC, and EAE was evaluated clinically. To test for the presence and the phenotype of T regulatory cells, CD4 and/or CD8 T cells from tolerogenic APC-treated mice were transferred to naive mice before their immunization with MBP. The MBP-specific tolerogenic APC decreased both the severity and incidence of ongoing EAE. Tolerance to self-neuronal Ags was induced in naive recipient mice via adoptive transfer of CD8(+), but not CD4(+) T cells. Rational use of in vitro-generated tolerogenic APC may lead to novel therapy for autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764660     DOI: 10.4049/jimmunol.172.4.1991

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  Antigen-specific splenic CD4+ and CD8+ regulatory T cells generated via the eye, suppress experimental autoimmune encephalomyelitis either at the priming or at the effector phase.

Authors:  Sourojit Bhowmick; Robert B Clark; Stefan Brocke; Robert E Cone
Journal:  Int Immunol       Date:  2011-01-27       Impact factor: 4.823

Review 2.  Targeting stroma to treat cancers.

Authors:  Boris Engels; Donald A Rowley; Hans Schreiber
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

3.  TGF-beta-treated antigen presenting cells suppress collagen- induced arthritis through the promotion of Th2 responses.

Authors:  Sundo Jung; Yoon-Kyung Park; Hyunji Lee; Jung Hoon Shin; Gap Ryol Lee; Se-Ho Park
Journal:  Exp Mol Med       Date:  2010-03-31       Impact factor: 8.718

Review 4.  A Distinct Region in Erythropoietin that Induces Immuno/Inflammatory Modulation and Tissue Protection.

Authors:  RuiRong Yuan; Bo Wang; Wei Lu; Yasuhiro Maeda; Peter Dowling
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

5.  CD8+ regulatory T cells generated by neonatal recognition of peripheral self-antigen.

Authors:  Roland Reibke; Natalio Garbi; Ruth Ganss; Günter J Hämmerling; Bernd Arnold; Thilo Oelert
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-28       Impact factor: 11.205

6.  Dendritic cells treated with resveratrol during differentiation from monocytes gain substantial tolerogenic properties upon activation.

Authors:  Urban Svajger; Natasa Obermajer; Matjaz Jeras
Journal:  Immunology       Date:  2009-11-25       Impact factor: 7.397

7.  Indoleamine-2,3-dioxygenase enzyme expression and activity in polarized dendritic cells.

Authors:  Benita Wolf; David Posnick; Jan L Fisher; Lionel D Lewis; Marc S Ernstoff
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

8.  Regulation of interphotoreceptor retinoid-binding protein (IRBP)-specific Th1 and Th17 cells in anterior chamber-associated immune deviation (ACAID).

Authors:  Yan Cui; Hui Shao; Deming Sun; Henry J Kaplan
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-05-20       Impact factor: 4.799

9.  Antigen presenting cells treated in vitro by macrophage colony-stimulating factor and autoantigen protect mice from autoimmunity.

Authors:  Yangtai Guan; Shuo Yu; Zhao Zhao; Bogoljub Ciric; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  J Neuroimmunol       Date:  2007-11-19       Impact factor: 3.478

10.  Increased expression of Foxp3 in splenic CD8+ T cells from mice with anterior chamber-associated immune deviation.

Authors:  Liqiong Jiang; Peizeng Yang; Hao He; Bing Li; Xiaomin Lin; Shengping Hou; Hongyan Zhou; Xiangkun Huang; Kijlstra Aize
Journal:  Mol Vis       Date:  2007-06-19       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.